| Literature DB >> 35891674 |
Eray Yıldız1, Şevket Arslan1, Fatih Çölkesen1, Recep Evcen1, Filiz Sadi Aykan1, Mehmet Kılınç1.
Abstract
Background: Despite the worldwide increase in life expectancy and the elderly population, very little is known about the characteristics of anaphylaxis in older adults.Entities:
Keywords: Adrenaline; Anaphylaxis; Drug hypersensitivity; Hospitalization; Older adults
Year: 2022 PMID: 35891674 PMCID: PMC9293944 DOI: 10.1016/j.waojou.2022.100665
Source DB: PubMed Journal: World Allergy Organ J ISSN: 1939-4551 Impact factor: 5.516
Fig. 1Flow chart of the patients included in the study. WAO, World Allergy Organization
Clinical characteristics of anaphylaxis patients.
| Adults (18–64 years) n (%) | Older adults (≥65 years) n (%) | p | |
|---|---|---|---|
| Total | 887 (91.3) | 84 (8.7) | |
| 38 (18–64) | 68 (65–87) | ||
| Female | 551 (62.1) | 47 (56) | 0.267 |
| Male | 336 (37.9) | 37 (44) | 0.267 |
| 240 (27) | 12 (14.3) | ||
| 401 (45.2) | 76 (90.4) | ||
| Asthma and other respiratory diseases | 161 (18.1) | 29 (34.5) | |
| Cardiovascular diseases | 141 (15.9) | 64 (73.6) | |
| Diabetes mellitus | 75 (8.5) | 20 (23.8) | |
| Neuropsychiatric diseases | 51 (5.7) | 6 (7.1) | 0.604 |
| Thyroid diseases | 38 (4.3) | 3 (3.6) | 0.756 |
| Rheumatological diseases | 27 (3.0) | 2 (2.4) | 0.733 |
| Malignant diseases | 18 (2) | 4 (4.7) | 0.108 |
| Gastrointestinal-liver diseases | 14 (1.6) | 3 (3.6) | 0.682 |
| 240 (27) | 55 (65.5) | ||
| ACE inhibitors | 39 (4.4) | 22 (26.2) | |
| Beta blockers | 69 (7.8) | 27 (32.1) | |
| NSAIDs | 172 (19.4) | 25 (29.8) |
ACE, angiotensin converting enzyme; NSAIDs, nonsteroidal anti-inflammatory drugs.
Chi Square test (data were shown as number and percentages)
Comparison of anaphylaxis triggers in the adults and older adults.
| Adults (18–64 years) n (%) | Older adults (≥65 years) n (%) | p | |
|---|---|---|---|
| Total | 887 (91.3) | 84 (8.7) | |
| 554 (62.4) | 62 (73.8) | ||
| NSAIDs | 248 (44.7) | 24 (38.7) | 0.905 |
| Antibiotics | 214 (38.6) | 26 (41.9) | 0.166 |
| Beta lactams | 173 (81) | 20 (77) | 0.635 |
| Non-beta lactams | 41 (19) | 6 (23) | 0.635 |
| Proton pump inhibitors | 23 (4.2) | 2 (3.2) | 0.907 |
| Contrast agents | 17 (3.0) | 1 (1.6) | 0.637 |
| Local anesthetics | 12 (2.1) | 1 (1.6) | 0.901 |
| 226 (25.5) | 17 (20.2) | 0.289 | |
| Vespula spp. | 80 (35.4) | 7 (41.2) | 0.833 |
| Apis mellifera | 62 (27.4) | 5 (29.4) | 0.720 |
| Apis mellifera + Vespula spp. | 63 (27.9) | 4 (23.5) | 0.419 |
| Unknown | 21 (9.3) | 1 (5.9) | 0.488 |
| 76 (8.6) | 1 (1.2) | ||
| Egg whole | 13 | 0 | – |
| Walnut | 12 | 0 | – |
| Peanut | 10 | 1 | 0.958 |
| Peach | 10 | 0 | – |
| Almond | 8 | 0 | – |
| 12 (1.4) | 1 (1.2) | 0.901 | |
| 19 (2.1) | 3 (3.6) | 0.400 |
NSAID, nonsteroidal anti-inflammatory drugs.
Chi Square test (data were shown as number and percentages)
Comparison of clinical features of anaphylaxis in the adults and older adults.
| Adults (18–64 years) n (%) | Older adults (≥65 years) n (%) | p | |
|---|---|---|---|
| 887 (91.3) | 84 (8.7) | ||
| Mucocutaneous | 760 (85.7) | 64 (76.2) | |
| Respiratory | 702 (79) | 54 (64.3) | |
| Cardiovascular | 395 (44.5) | 56 (66.6) | |
| Gastrointestinal | 124 (14) | 11 (13.1) | 0.852 |
| Grade III | 372 (41.9) | 40 (47.6) | 0.314 |
| Grade IV | 424 (47.8) | 27 (32.1) | |
| Grade V | 91 (10.3) | 17 (20.3) | |
| 33 (3.7) | 1 (1.2) | 0.228 | |
| 108 (12.2) | 31 (36.9) | ||
| 71 (8) | 13 (15.5) |
ICU, intensive care unit.
Chi Square test (data were shown as number and percentages)
Fig. 2Rates of hospitalization and intensive care unit admissions by severity of anaphylaxis. ICU, intensive care unit. ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns, not significant
Comparison of anaphylaxis treatment in the adults and older adults.
| Adults (18–64 years) n (%) | Older adults (≥65 years) n (%) | p | |
|---|---|---|---|
| Total | 887 (91.3) | 84 (8.7) | |
| Antihistamines (H1 and/or H2) | 836 (94.2) | 77 (91.7) | 0.340 |
| Steroids | 810 (91.3) | 74 (88.1) | 0.323 |
| Epinephrine | 252 (28.4) | 43 (53.1) | |
| 330 (37.2) | 24 (28.6) | 0.116 | |
| 96 (10.8) | 2 (2.4) |
Chi Square test (data were shown as number and percentages).
Venom immunotherapy
Fig. 3Adrenaline administration rates according to the severity of anaphylaxis. ∗∗p < 0.001; ∗p < 0.05; ns, not significant
Anaphylaxis risk factors in the older adults.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Variables | OR | 95% CI | p | OR | 95% CI | p |
| Sex (female vs. male) | 0.775 | 0.493–1.217 | 0.268 | |||
| Comorbidity (yes vs. no) | 11.514 | 5.491–24.142 | 7.527 | 3.487–16.249 | ||
| ACE inhibitor use (yes vs. no) | 7.715 | 4.308–13.818 | 3.405 | 1.849–6.272 | ||
| Beta-blocker use (yes vs. no) | 5.616 | 3.340–9.442 | 2.375 | 1.364–4.135 | ||
OR, odds ratio; CI, confidence interval